Browsing by Author "Fatima Laher"
Now showing 1 - 8 of 8
- Results Per Page
- Sort Options
Item Factors associated with reactogenicity to an investigational HIV vaccine regimen in HIV vaccine trials network 702R Chihana; J J Kee; Z Moodie; Y Huang; Glenda Gray; E et al; Fatima LaherItem Impact of vaccine type on HIV1 vaccine elicited antibody durability and B cell gene signatureR Palli; K Seaton; M Piepenbrink; J Hural; Fatima Laher; Gavin Churchyard; Glenda Gray; E et alItem NonHIV VaccineInduced Immune Responses as Potential Baseline Immunogenicity Predictors of ALVAXHIV and AIDSVAX BEInduced Immune ResponsesYing Huang; Shomoita Alam; Erica Andersen Nissen; L Carpp; E et al; Fatima Laher; Glenda GrayItem Protein DoseSparing Effect of AS01B Adjuvant in a Randomized Preventive HIV Vaccine Trial of ALVACHIV vCP2438 and Adjuvanted Bivalent Subtype C gp120(OXFORD UNIV PRESS INC) Z M Chirenje; Fatima Laher; O Dintwe; M Muyoyeta; A C deCamp; E et alItem Safety and immunogenicity after a 30month boost of a subtype C ALVACHIV vCP2438 vaccine prime plus bivalent subtype C gp120 MF59 vaccine boost HVTN 100 A phase 12 randomized doubleblind placebocontrolled trialVimla Naicker; Fatima Laher; L Bekker; K Seaton; M Allen; E et al; Lynn Morris; Nonhlanhla MkhizeItem Safety and immunogenicity of a subtype C ALVACHIV vCP2438 vaccine prime plus bivalent subtype C gp120 vaccine boost adjuvanted with MF59 or alum in healthy adults without HIV HVTN 107 A phase 12a randomized trial(PUBLIC LIBRARY SCIENCE) Z Moodie; E Andersen-Nissen; Nicole Grunenberg; One B Dintwe; Fatima Laher; E et alItem Thrombosis AETiology of Aviation-Related Travel: The THETA O Study(WILEY-BLACKWELL) Barry Jacobson; Susan Louw; Elise Schapkaitz; Fatima LaherItem Use of Varied Screening Risk Criteria and HIV Incidence in Phase 1 and 2 HIV Vaccine Trials in South Africa(SPRINGER/PLENUM PUBLISHERS) Fatima Laher; Kennedy Otwombe; Ofentse Mokwena; L G Bekker; M Allen